SRMS142-based solid lipid microparticles: Application in oral delivery of glibenclamide to diabetic rats

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 76, Issue 1, 2010, Pages 68-74

  Nnamani, P O ^a,b   Attama, A A ^a   Ibezim, E C ^a   Adikwu, M U ^a,c  

^a UNIVERSITY OF NIGERIA   (Nigeria)

^b CBM Srl Area Science Park   (Italy)

^c Science and Technology Education Post Basic (STEP B)   (Nigeria)

Author keywords

Glibenclamide; P90Gylation; Solid lipid microparticles; SRMS142

Indexed keywords

ASCORBYL PALMITATE; DRUG CARRIER; EXCIPIENT; GLIBENCLAMIDE; GLUCOSE; PHOSPHATIDYLCHOLINE; SOLID LIPID NANOPARTICLE; WETTING AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EMULSION; ENCAPSULATION; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; MALE; NONHUMAN; RAT;

EID: 77955662124     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.06.002     Document Type: Article

References (24)

1. Friedrich I., Müller-Goymann C.C. Characterization of solidified reverse micellar solutions (SRMS) and production development of SRMS-based nanosuspensions. Eur. J. Pharm. Biopharm. 2003, 56(1):111-199.
2. Friedrich I., Reichi S., Müller-Goymann C.C. Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS). Int. J. Pharm. 2005, 305(1-2):167-175.
3. Millqvist-Fureby P.S. In-situ lecithination of dairy powders in spray-drying for confectionery applications. Food Hydrocolloid. 2007, 21:920-927.
4. Radtke M., Müller R.H. Nanostructured lipid carriers: the new generation of lipid drug carriers. New Drugs 2001, 2:48-52.
5. Schubert M.A., Müller-Goyman C.C. Solvent injection as a new approach for manufacturing lipid nanoparticles - evaluation of the method and process parameters. Eur. J. Pharm. Biopharm. 2003, 55:125-131.
6. Lanza G.M., Yu X., Winter P.M., Abendschein D.R., Karukstis K.K., Scott M.J., Chinen L.K., Fuhrhop R.W., Scherrer D.E., Wickline S.A. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 2002, 106:2842-2847.
7. Herr J.K., Smith J.E., Medley C.D., Shangguan D., Tan W. Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells. Anal. Chem. 2006, 78:2918-2924.
8. Paciotti G.F., Myer L., Weinreich D., Goia D., Pavel N., McLaughlin R.E., Tamarkin L. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv. 2004, 11:169-183.
9. Barth R.F., Adams D.M., Soloway A.H., Alam F., Darby M.V. Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. Bioconjugate Chem. 1994, 5:58-66.
10. Oyewumi M.O., Yokel R.A., Jay M., et al. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J. Control. Release 2004, 95:613-626.
11. Zhang J.Z. Surface modification of monodisperse magnetite nanoparticles for improved intracellular uptake to breast cancer cells. J. Colloids Interface Sci. 2005, 283:352-357.
12. Müller R.H., Radtke M., Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 2002, 54(Suppl. 1):S131-S155.
13. Abuchowsky A., et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 1977, 252:3578-3581.
14. Abuchowsky A., Davis F.F., et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 1977, 252:3582-3586.
15. Savoca K.V., Davis F.F., Van E.T., et al. Cancer therapy with chemically modified enzymes. II. The therapeutic effectiveness of arginase, and arginase modified by the covalent attachment of polyethylene glycol, on the taper liver tumor and the L5178Y murine leukemia. Cancer Biochem. Biophys. 1984, 7:261-268.
16. Otsuka H., Nagasaki Y., Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv. Drug Deliv. Rev. 2003, 55:403-419.
17. Tobio M., Sánchez A., Vila A., Soriano I., et al. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloid Surf. B: Biointerfaces 2000, 18:315-323.
18. Vila A., Gill H., McCallion O., Alonso M.J. Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J. Control. Release 2004, 98:231-244.
19. Schneeweis A., Müller-Goymann C.C. Controlled release of solid-reversed-micellar-solution (SRMS) suppositories containing metoclopramide-HCl. Int. J. Pharm. 2000, 196(2):193-196.
20. Toongsuwan S., Li C.K., Erickson B.K., Chang H.C. Formulation and characterization of bupivacaine lipospheres. Int. J. Pharm. 2004, 280(1-2):57-65.
21. Jaspart S., Piel G., Delatte L., Evrard B. Solid lipid microparticles: formulation, preparation, characterization, drug release and applications. Expert Opin. Drug Deliv. 2005, 2:75-87.
22. Sanna V., Kirschvink N., Gustin P., Gavini E., Roland I., Delattre L., Evrard B. Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration. AAPS Pharm. Sci. Technol. 2004, 5(2). (Article 27).
23. Kim B.D., Na K., Choi H.-K. Preparation and characterization of solid lipid nanoparticles (SLN) made of cocoa butter and curdlan. Eur. J. Pharm. Sci. 2005, 24:199-205.
24. Attama A.A., Müller-Goymann C.C. A critical study of novel physically structured lipid matrices composed of a homolipid from Capra hircus and theobroma oil. Int. J. Pharm. 2006, 322:67-78.